PPAR agonists and the metabolic syndrome
- PMID: 17983557
- DOI: 10.2515/therapie:2007051
PPAR agonists and the metabolic syndrome
Abstract
Cardiovascular disease is significantly increased in patients with the metabolic syndrome and type 2 diabetes. A clustering of risk factors, including dyslipidemia, insulin resistance, hypertension, inflammation and coagulation disorders are likely to promote cardiovascular events in these patients. Peroxisome proliferator-activated receptors (PPARs) represent one important pathway that influence vascular function both directly and indirectly by altering gene expression. Indeed, PPAR activation induces beneficial effects not only on glucose homeostasis and lipid metabolism but also on endothelial function and vessel wall inflammation. PPAR agonists such as fibrates (PPARalpha) and insulin-sensitizing thiazolidinediones (PPARgamma) are in clinical use and may alter the process of atherosclerosis, especially in subjects with the metabolic syndrome and type 2 diabetes. This review will highlight the emerging evidence for the beneficial effects of PPAR agonists in the prevention and treatment of atherosclerosis in such high-risk patients.
Similar articles
-
PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.Curr Opin Investig Drugs. 2004 Sep;5(9):936-40. Curr Opin Investig Drugs. 2004. PMID: 15503647 Review.
-
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).Acta Med Indones. 2006 Jul-Sep;38(3):160-6. Acta Med Indones. 2006. PMID: 17119268 Review.
-
Therapeutical effects of PPAR agonists assessed by biomarker modulation.Biomarkers. 2005 Nov;10 Suppl 1:S30-6. doi: 10.1080/13547500500216702. Biomarkers. 2005. PMID: 16298909 Review.
-
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. doi: 10.1016/j.beem.2007.09.004. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 18054742 Review.
-
Strategies for the development of new PPAR agonists in diabetes.Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S32-7. doi: 10.1097/01.hjr.0000368196.17109.5e. Eur J Cardiovasc Prev Rehabil. 2010. PMID: 20489419 Review.
Cited by
-
Allometric prediction of the human pharmacokinetic parameters for naveglitazar.Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):187-90. doi: 10.1007/BF03191117. Eur J Drug Metab Pharmacokinet. 2008. PMID: 19007045
-
In Silico-Based Design and In Vivo Evaluation of an Anthranilic Acid Derivative as a Multitarget Drug in a Diet-Induced Metabolic Syndrome Model.Pharmaceuticals (Basel). 2021 Sep 10;14(9):914. doi: 10.3390/ph14090914. Pharmaceuticals (Basel). 2021. PMID: 34577613 Free PMC article.
-
Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.Nature. 2008 Nov 20;456(7220):350-6. doi: 10.1038/nature07413. Nature. 2008. PMID: 19043829 Free PMC article.
-
PPARα Protein Expression Was Increased by Four Weeks of Intermittent Hypoxic Training via AMPKα2-Dependent Manner in Mouse Skeletal Muscle.PLoS One. 2015 Apr 29;10(4):e0122593. doi: 10.1371/journal.pone.0122593. eCollection 2015. PLoS One. 2015. PMID: 25923694 Free PMC article.
-
The peroxisome: still a mysterious organelle.Histochem Cell Biol. 2008 Apr;129(4):421-40. doi: 10.1007/s00418-008-0396-9. Epub 2008 Feb 15. Histochem Cell Biol. 2008. PMID: 18274771 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
